Loading…
Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan
Vaccine effectiveness against SARS-CoV-2 infections decreases due to waning immunity, and booster vaccination was therefore introduced. We estimated the anti-spike antibody (AS-ab) recovery by booster vaccination and analyzed the risk factors for SARS-CoV-2 infections. The subjects were health care...
Saved in:
Published in: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2022-11, Vol.28 (11), p.1483-1488 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c545t-b8b635d7c8f0b9669c72b1d545e22ff997db6d07b6471e2695d974922cce09de3 |
---|---|
cites | cdi_FETCH-LOGICAL-c545t-b8b635d7c8f0b9669c72b1d545e22ff997db6d07b6471e2695d974922cce09de3 |
container_end_page | 1488 |
container_issue | 11 |
container_start_page | 1483 |
container_title | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
container_volume | 28 |
creator | Igari, Hidetoshi Asano, Haruna Murata, Shota Yoshida, Toshihiko Kawasaki, Kenji Kageyama, Takahiro Ikeda, Key Koshikawa, Hiromi Okuda, Yoshio Urushihara, Misao Chiba, Hitoshi Yahaba, Misuzu Taniguchi, Toshibumi Matsushita, Kazuyuki Yoshino, Ichiro Yokote, Koutaro Nakajima, Hiroshi |
description | Vaccine effectiveness against SARS-CoV-2 infections decreases due to waning immunity, and booster vaccination was therefore introduced. We estimated the anti-spike antibody (AS-ab) recovery by booster vaccination and analyzed the risk factors for SARS-CoV-2 infections.
The subjects were health care workers (HCWs) in a Chiba University Hospital vaccination cohort. They had received two doses of vaccine (BNT162b2) and a booster vaccine (BNT162b2). We retrospectively analyzed AS-ab titers and watched out for SARS-CoV-2 infection for 90 days following booster vaccination.
AS-ab titer eight months after two-dose vaccinations had decreased to as low as 587 U/mL (median, IQR (interquartile range) 360–896). AS-ab titer had then increased to 22471 U/mL (15761–32622) three weeks after booster vaccination. There were no significant differences among age groups.
A total of 1708 HCWs were analyzed for SARS-CoV-2 infection, and 48 of them proved positive. SARS-CoV-2 infections in the booster-vaccinated and non-booster groups were 1.8% and 4.0%, respectively, and were not significant. However, when restricted to those 20–29 years old, SARS-CoV-2 infections in the booster-vaccinated and non-booster groups were 2.9% and 13.6%, respectively (p = 0.04). After multivariate logistic regression, COVID-19 wards (adjusted odds ratio (aOR):2.9, 95% confidence interval (CI) 1.5–5.6) and those aged 20–49 years (aOR:9.7, 95%CI 1.3–71.2) were risk factors for SARS-CoV-2 infection.
Booster vaccination induced the recovery of AS-ab titers. Risk factors for SARS-CoV-2 infection were HCWs of COVID-19 wards and those aged 20–49 years. Increased vaccination coverage, together with implementing infection control, remains the primary means of preventing HCWs from SARS-CoV-2 infection. |
doi_str_mv | 10.1016/j.jiac.2022.07.010 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9296373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1341321X22002069</els_id><sourcerecordid>2693780192</sourcerecordid><originalsourceid>FETCH-LOGICAL-c545t-b8b635d7c8f0b9669c72b1d545e22ff997db6d07b6471e2695d974922cce09de3</originalsourceid><addsrcrecordid>eNp9kUtv1DAURiNERUvhD7BAXrJJ8COxYwkhDSNeVVWktiB2lh83HQ-JPdiZQf339WjaCjasbPl-91zrnqp6RXBDMOFv183aa9tQTGmDRYMJflKdkJaJWogePy131pKaUfLzuHqe8xpjIrq-f1Yds64XWEhyUm0XYfYmuluUIG9iyJCRDg5dLS6v6mX8UVPkwwB29jEgPcyQ0IeLa8KpoWi6vFggE2Pev-60tT7oQ26K4QatQI_zyuoE6E9MvyDlgkJneqPDi-po0GOGl_fnafX908fr5Zf6_Nvnr8vFeW27tptr0xvOOidsP2AjOZdWUENcqQGlwyClcIY7LAxvBQHKZeekaCWl1gKWDthp9f7A3WzNBM5CmJMe1Sb5SadbFbVX_1aCX6mbuFOSSs4EK4A394AUf28hz2ry2cI46gBxm1WZycquiaQlSg9Rm2LOCYbHMQSrvS-1Vntfau9LYaGKr9L0-u8PPrY8CCqBd4cAlDXtPCSVrYdgwflUrCgX_f_4d-yYp6M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2693780192</pqid></control><display><type>article</type><title>Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Igari, Hidetoshi ; Asano, Haruna ; Murata, Shota ; Yoshida, Toshihiko ; Kawasaki, Kenji ; Kageyama, Takahiro ; Ikeda, Key ; Koshikawa, Hiromi ; Okuda, Yoshio ; Urushihara, Misao ; Chiba, Hitoshi ; Yahaba, Misuzu ; Taniguchi, Toshibumi ; Matsushita, Kazuyuki ; Yoshino, Ichiro ; Yokote, Koutaro ; Nakajima, Hiroshi</creator><creatorcontrib>Igari, Hidetoshi ; Asano, Haruna ; Murata, Shota ; Yoshida, Toshihiko ; Kawasaki, Kenji ; Kageyama, Takahiro ; Ikeda, Key ; Koshikawa, Hiromi ; Okuda, Yoshio ; Urushihara, Misao ; Chiba, Hitoshi ; Yahaba, Misuzu ; Taniguchi, Toshibumi ; Matsushita, Kazuyuki ; Yoshino, Ichiro ; Yokote, Koutaro ; Nakajima, Hiroshi</creatorcontrib><description>Vaccine effectiveness against SARS-CoV-2 infections decreases due to waning immunity, and booster vaccination was therefore introduced. We estimated the anti-spike antibody (AS-ab) recovery by booster vaccination and analyzed the risk factors for SARS-CoV-2 infections.
The subjects were health care workers (HCWs) in a Chiba University Hospital vaccination cohort. They had received two doses of vaccine (BNT162b2) and a booster vaccine (BNT162b2). We retrospectively analyzed AS-ab titers and watched out for SARS-CoV-2 infection for 90 days following booster vaccination.
AS-ab titer eight months after two-dose vaccinations had decreased to as low as 587 U/mL (median, IQR (interquartile range) 360–896). AS-ab titer had then increased to 22471 U/mL (15761–32622) three weeks after booster vaccination. There were no significant differences among age groups.
A total of 1708 HCWs were analyzed for SARS-CoV-2 infection, and 48 of them proved positive. SARS-CoV-2 infections in the booster-vaccinated and non-booster groups were 1.8% and 4.0%, respectively, and were not significant. However, when restricted to those 20–29 years old, SARS-CoV-2 infections in the booster-vaccinated and non-booster groups were 2.9% and 13.6%, respectively (p = 0.04). After multivariate logistic regression, COVID-19 wards (adjusted odds ratio (aOR):2.9, 95% confidence interval (CI) 1.5–5.6) and those aged 20–49 years (aOR:9.7, 95%CI 1.3–71.2) were risk factors for SARS-CoV-2 infection.
Booster vaccination induced the recovery of AS-ab titers. Risk factors for SARS-CoV-2 infection were HCWs of COVID-19 wards and those aged 20–49 years. Increased vaccination coverage, together with implementing infection control, remains the primary means of preventing HCWs from SARS-CoV-2 infection.</description><identifier>ISSN: 1341-321X</identifier><identifier>ISSN: 1437-7780</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1016/j.jiac.2022.07.010</identifier><identifier>PMID: 35870791</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Anti-spike antibody ; Antibodies, Viral ; Antibody Formation ; BNT162 Vaccine ; Booster vaccination ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; Health Personnel ; Healthcare worker ; Humans ; Japan - epidemiology ; mRNA vaccine ; Original ; Retrospective Studies ; RNA, Messenger ; SARS-CoV-2 ; Vaccination ; Vaccines ; Young Adult</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022-11, Vol.28 (11), p.1483-1488</ispartof><rights>2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control</rights><rights>Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><rights>2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c545t-b8b635d7c8f0b9669c72b1d545e22ff997db6d07b6471e2695d974922cce09de3</citedby><cites>FETCH-LOGICAL-c545t-b8b635d7c8f0b9669c72b1d545e22ff997db6d07b6471e2695d974922cce09de3</cites><orcidid>0000-0003-3033-4813 ; 0000-0001-7754-3458 ; 0000-0002-9450-5848 ; 0000-0001-8595-9381</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35870791$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Igari, Hidetoshi</creatorcontrib><creatorcontrib>Asano, Haruna</creatorcontrib><creatorcontrib>Murata, Shota</creatorcontrib><creatorcontrib>Yoshida, Toshihiko</creatorcontrib><creatorcontrib>Kawasaki, Kenji</creatorcontrib><creatorcontrib>Kageyama, Takahiro</creatorcontrib><creatorcontrib>Ikeda, Key</creatorcontrib><creatorcontrib>Koshikawa, Hiromi</creatorcontrib><creatorcontrib>Okuda, Yoshio</creatorcontrib><creatorcontrib>Urushihara, Misao</creatorcontrib><creatorcontrib>Chiba, Hitoshi</creatorcontrib><creatorcontrib>Yahaba, Misuzu</creatorcontrib><creatorcontrib>Taniguchi, Toshibumi</creatorcontrib><creatorcontrib>Matsushita, Kazuyuki</creatorcontrib><creatorcontrib>Yoshino, Ichiro</creatorcontrib><creatorcontrib>Yokote, Koutaro</creatorcontrib><creatorcontrib>Nakajima, Hiroshi</creatorcontrib><title>Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J Infect Chemother</addtitle><description>Vaccine effectiveness against SARS-CoV-2 infections decreases due to waning immunity, and booster vaccination was therefore introduced. We estimated the anti-spike antibody (AS-ab) recovery by booster vaccination and analyzed the risk factors for SARS-CoV-2 infections.
The subjects were health care workers (HCWs) in a Chiba University Hospital vaccination cohort. They had received two doses of vaccine (BNT162b2) and a booster vaccine (BNT162b2). We retrospectively analyzed AS-ab titers and watched out for SARS-CoV-2 infection for 90 days following booster vaccination.
AS-ab titer eight months after two-dose vaccinations had decreased to as low as 587 U/mL (median, IQR (interquartile range) 360–896). AS-ab titer had then increased to 22471 U/mL (15761–32622) three weeks after booster vaccination. There were no significant differences among age groups.
A total of 1708 HCWs were analyzed for SARS-CoV-2 infection, and 48 of them proved positive. SARS-CoV-2 infections in the booster-vaccinated and non-booster groups were 1.8% and 4.0%, respectively, and were not significant. However, when restricted to those 20–29 years old, SARS-CoV-2 infections in the booster-vaccinated and non-booster groups were 2.9% and 13.6%, respectively (p = 0.04). After multivariate logistic regression, COVID-19 wards (adjusted odds ratio (aOR):2.9, 95% confidence interval (CI) 1.5–5.6) and those aged 20–49 years (aOR:9.7, 95%CI 1.3–71.2) were risk factors for SARS-CoV-2 infection.
Booster vaccination induced the recovery of AS-ab titers. Risk factors for SARS-CoV-2 infection were HCWs of COVID-19 wards and those aged 20–49 years. Increased vaccination coverage, together with implementing infection control, remains the primary means of preventing HCWs from SARS-CoV-2 infection.</description><subject>Adult</subject><subject>Anti-spike antibody</subject><subject>Antibodies, Viral</subject><subject>Antibody Formation</subject><subject>BNT162 Vaccine</subject><subject>Booster vaccination</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>Health Personnel</subject><subject>Healthcare worker</subject><subject>Humans</subject><subject>Japan - epidemiology</subject><subject>mRNA vaccine</subject><subject>Original</subject><subject>Retrospective Studies</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Young Adult</subject><issn>1341-321X</issn><issn>1437-7780</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kUtv1DAURiNERUvhD7BAXrJJ8COxYwkhDSNeVVWktiB2lh83HQ-JPdiZQf339WjaCjasbPl-91zrnqp6RXBDMOFv183aa9tQTGmDRYMJflKdkJaJWogePy131pKaUfLzuHqe8xpjIrq-f1Yds64XWEhyUm0XYfYmuluUIG9iyJCRDg5dLS6v6mX8UVPkwwB29jEgPcyQ0IeLa8KpoWi6vFggE2Pev-60tT7oQ26K4QatQI_zyuoE6E9MvyDlgkJneqPDi-po0GOGl_fnafX908fr5Zf6_Nvnr8vFeW27tptr0xvOOidsP2AjOZdWUENcqQGlwyClcIY7LAxvBQHKZeekaCWl1gKWDthp9f7A3WzNBM5CmJMe1Sb5SadbFbVX_1aCX6mbuFOSSs4EK4A394AUf28hz2ry2cI46gBxm1WZycquiaQlSg9Rm2LOCYbHMQSrvS-1Vntfau9LYaGKr9L0-u8PPrY8CCqBd4cAlDXtPCSVrYdgwflUrCgX_f_4d-yYp6M</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Igari, Hidetoshi</creator><creator>Asano, Haruna</creator><creator>Murata, Shota</creator><creator>Yoshida, Toshihiko</creator><creator>Kawasaki, Kenji</creator><creator>Kageyama, Takahiro</creator><creator>Ikeda, Key</creator><creator>Koshikawa, Hiromi</creator><creator>Okuda, Yoshio</creator><creator>Urushihara, Misao</creator><creator>Chiba, Hitoshi</creator><creator>Yahaba, Misuzu</creator><creator>Taniguchi, Toshibumi</creator><creator>Matsushita, Kazuyuki</creator><creator>Yoshino, Ichiro</creator><creator>Yokote, Koutaro</creator><creator>Nakajima, Hiroshi</creator><general>Elsevier Ltd</general><general>Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3033-4813</orcidid><orcidid>https://orcid.org/0000-0001-7754-3458</orcidid><orcidid>https://orcid.org/0000-0002-9450-5848</orcidid><orcidid>https://orcid.org/0000-0001-8595-9381</orcidid></search><sort><creationdate>20221101</creationdate><title>Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan</title><author>Igari, Hidetoshi ; Asano, Haruna ; Murata, Shota ; Yoshida, Toshihiko ; Kawasaki, Kenji ; Kageyama, Takahiro ; Ikeda, Key ; Koshikawa, Hiromi ; Okuda, Yoshio ; Urushihara, Misao ; Chiba, Hitoshi ; Yahaba, Misuzu ; Taniguchi, Toshibumi ; Matsushita, Kazuyuki ; Yoshino, Ichiro ; Yokote, Koutaro ; Nakajima, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c545t-b8b635d7c8f0b9669c72b1d545e22ff997db6d07b6471e2695d974922cce09de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Anti-spike antibody</topic><topic>Antibodies, Viral</topic><topic>Antibody Formation</topic><topic>BNT162 Vaccine</topic><topic>Booster vaccination</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>Health Personnel</topic><topic>Healthcare worker</topic><topic>Humans</topic><topic>Japan - epidemiology</topic><topic>mRNA vaccine</topic><topic>Original</topic><topic>Retrospective Studies</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Igari, Hidetoshi</creatorcontrib><creatorcontrib>Asano, Haruna</creatorcontrib><creatorcontrib>Murata, Shota</creatorcontrib><creatorcontrib>Yoshida, Toshihiko</creatorcontrib><creatorcontrib>Kawasaki, Kenji</creatorcontrib><creatorcontrib>Kageyama, Takahiro</creatorcontrib><creatorcontrib>Ikeda, Key</creatorcontrib><creatorcontrib>Koshikawa, Hiromi</creatorcontrib><creatorcontrib>Okuda, Yoshio</creatorcontrib><creatorcontrib>Urushihara, Misao</creatorcontrib><creatorcontrib>Chiba, Hitoshi</creatorcontrib><creatorcontrib>Yahaba, Misuzu</creatorcontrib><creatorcontrib>Taniguchi, Toshibumi</creatorcontrib><creatorcontrib>Matsushita, Kazuyuki</creatorcontrib><creatorcontrib>Yoshino, Ichiro</creatorcontrib><creatorcontrib>Yokote, Koutaro</creatorcontrib><creatorcontrib>Nakajima, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Igari, Hidetoshi</au><au>Asano, Haruna</au><au>Murata, Shota</au><au>Yoshida, Toshihiko</au><au>Kawasaki, Kenji</au><au>Kageyama, Takahiro</au><au>Ikeda, Key</au><au>Koshikawa, Hiromi</au><au>Okuda, Yoshio</au><au>Urushihara, Misao</au><au>Chiba, Hitoshi</au><au>Yahaba, Misuzu</au><au>Taniguchi, Toshibumi</au><au>Matsushita, Kazuyuki</au><au>Yoshino, Ichiro</au><au>Yokote, Koutaro</au><au>Nakajima, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><addtitle>J Infect Chemother</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>28</volume><issue>11</issue><spage>1483</spage><epage>1488</epage><pages>1483-1488</pages><issn>1341-321X</issn><issn>1437-7780</issn><eissn>1437-7780</eissn><abstract>Vaccine effectiveness against SARS-CoV-2 infections decreases due to waning immunity, and booster vaccination was therefore introduced. We estimated the anti-spike antibody (AS-ab) recovery by booster vaccination and analyzed the risk factors for SARS-CoV-2 infections.
The subjects were health care workers (HCWs) in a Chiba University Hospital vaccination cohort. They had received two doses of vaccine (BNT162b2) and a booster vaccine (BNT162b2). We retrospectively analyzed AS-ab titers and watched out for SARS-CoV-2 infection for 90 days following booster vaccination.
AS-ab titer eight months after two-dose vaccinations had decreased to as low as 587 U/mL (median, IQR (interquartile range) 360–896). AS-ab titer had then increased to 22471 U/mL (15761–32622) three weeks after booster vaccination. There were no significant differences among age groups.
A total of 1708 HCWs were analyzed for SARS-CoV-2 infection, and 48 of them proved positive. SARS-CoV-2 infections in the booster-vaccinated and non-booster groups were 1.8% and 4.0%, respectively, and were not significant. However, when restricted to those 20–29 years old, SARS-CoV-2 infections in the booster-vaccinated and non-booster groups were 2.9% and 13.6%, respectively (p = 0.04). After multivariate logistic regression, COVID-19 wards (adjusted odds ratio (aOR):2.9, 95% confidence interval (CI) 1.5–5.6) and those aged 20–49 years (aOR:9.7, 95%CI 1.3–71.2) were risk factors for SARS-CoV-2 infection.
Booster vaccination induced the recovery of AS-ab titers. Risk factors for SARS-CoV-2 infection were HCWs of COVID-19 wards and those aged 20–49 years. Increased vaccination coverage, together with implementing infection control, remains the primary means of preventing HCWs from SARS-CoV-2 infection.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>35870791</pmid><doi>10.1016/j.jiac.2022.07.010</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3033-4813</orcidid><orcidid>https://orcid.org/0000-0001-7754-3458</orcidid><orcidid>https://orcid.org/0000-0002-9450-5848</orcidid><orcidid>https://orcid.org/0000-0001-8595-9381</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1341-321X |
ispartof | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022-11, Vol.28 (11), p.1483-1488 |
issn | 1341-321X 1437-7780 1437-7780 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9296373 |
source | Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list) |
subjects | Adult Anti-spike antibody Antibodies, Viral Antibody Formation BNT162 Vaccine Booster vaccination COVID-19 - epidemiology COVID-19 - prevention & control Health Personnel Healthcare worker Humans Japan - epidemiology mRNA vaccine Original Retrospective Studies RNA, Messenger SARS-CoV-2 Vaccination Vaccines Young Adult |
title | Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A00%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20responses%20and%20SARS-CoV-2%20infection%20after%20BNT162b2%20mRNA%20booster%20vaccination%20among%20healthcare%20workers%20in%20Japan&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Igari,%20Hidetoshi&rft.date=2022-11-01&rft.volume=28&rft.issue=11&rft.spage=1483&rft.epage=1488&rft.pages=1483-1488&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1016/j.jiac.2022.07.010&rft_dat=%3Cproquest_pubme%3E2693780192%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c545t-b8b635d7c8f0b9669c72b1d545e22ff997db6d07b6471e2695d974922cce09de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2693780192&rft_id=info:pmid/35870791&rfr_iscdi=true |